TECHNICAL SPECIFICATIONS

1.MECHANISM OF ACTION

Cagrilintide functions by binding to and activating amylin receptors in the brain, specifically targeting areas like the area postrema and the hypothalamus, which are critical for regulating appetite and satiety. Its action involves delaying gastric emptying, which prolongs the feeling of fullness after meals, and suppressing postprandial glucagon secretion, thereby reducing overall caloric intake and promoting weight loss through a non-GLP-1 pathway that is complementary to incretin-based therapies.

2.PRODUCT INDICATIONS

Cagrilintide is indicated for the treatment of adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity, such as hypertension or dyslipidemia, but without type 2 diabetes. It is particularly suited for individuals seeking a non-stimulant, hormone-based therapy who may have experienced intolerance to the gastrointestinal side effects of GLP-1 medications, offering a well-tolerated option for long-term weight management.

3.CLINICAL EFFICACY OF PRODUCT

In the pivotal Phase 3 REDEFINE 1 trial, Cagrilintide monotherapy demonstrated robust clinical efficacy, with patients achieving an average weight loss of 11.8% over 68 weeks compared to 2.3% with placebo. Notably, approximately 31.6% of participants achieved a weight loss of 15% or more, highlighting its potential to deliver clinically meaningful outcomes. The therapy was well-tolerated, with gastrointestinal adverse events being predominantly mild to moderate in severity and transient, supporting its profile as a viable monotherapy for sustained weight reduction.

4.Certificate

GlobalTech Co., Ltd. is committed to providing high-purity biotechnological peptide products, adhering strictly to quality standards and obtaining internationally recognized certifications.

Our production partners all employ GMP-compliant production systems and possess standardized quality control processes covering raw material procurement, synthesis, purification, testing, packaging, and storage. Each batch of product comes with complete documentation, including a Certificate of Analysis (COA), HPLC purity report, mass spectrometry (MS) chromatograms, and third-party testing reports available upon request.

We prioritize:

1.A rigorous quality management system

2.Batch traceability and stability data

3.Professional laboratory testing and validation

4.Compliance with international trade standards

Our commitment to quality, transparency, and regulatory compliance ensures the provision of reliable, stable, and research-grade peptide products to our global partners.

5.DELIVERY & SHIPPING

We specialize in global logistics for various cosmetic peptides. Your order will be handled with the utmost care, ensuring safe, reliable, and intact delivery.

Professional and Secure Packaging

Each bottle of peptide is protected with a special packaging solution to ensure stability and integrity during transportation.

We can also customize packaging according to customer needs.

Shipping Methods 

Main Method: International Air Freight

We primarily use DHL, FedEx, UPS, and TNT because of their global reliability, speed, and advanced tracking systems. Air freight ensures the fastest transit time and minimizes the impact of environmental factors on the product.

Global Technology Co., Ltd. is a modern and advanced enterprise specializing in the production and export of active pharmaceutical ingredients (APIs), peptides, and plant extracts. The company invests in and collaborates closely with domestic manufacturers holding GMP, DMF, and FDA certifications, as well as laboratories at renowned universities, to meet diverse customer needs ranging from gram-level to ton-level. This enables Dejurui Pharmaceutical to provide customers with more flexible and convenient access to cost-effective, high-quality products and superior services.

We focus on the research and development and supply of high-quality chemical products, strictly adhering to international standards and quality systems. Our products are stable in performance and reliable in purity, widely used in industrial manufacturing, scientific research, and the fine chemical industry. We provide solid support at every stage with a professional and responsible attitude.

Hot Tags:Cagrilintide, AmylinAnalogue, WeightLoss, ObesityTreatment, NovoNordisk, MetabolicHealth, CagriSema, REDEFINE1, GLP1Alternative, OnceWeeklyInjection Supplier, Manufacturer, Bulk order,  Pharmaceutical.

If you have any product requirements, please send an email to:sales@huanqiukeji9.com;whatsapp:85244219157

What Does Cagrilintide Peptide Do?

Cagrilintide is a long-acting synthetic peptide that mimics the action of the natural hormone amylin, which is co-secreted with insulin by the pancreas. Its primary role is to regulate appetite, gastric emptying, and post-meal glucose levels, making it a promising agent for weight management and metabolic control.

One of the main functions of cagrilintide is appetite suppression. It acts on receptors in the brain, particularly in areas involved in hunger regulation, to increase feelings of satiety and reduce food intake. As a result, individuals tend to eat smaller portions and feel full for longer periods after meals. This effect is especially valuable in the treatment of obesity, where long-term appetite control is a major challenge.

Cagrilintide also slows gastric emptying, meaning food moves more gradually from the stomach into the intestines. This helps stabilize blood sugar levels after eating by preventing rapid spikes in glucose. Because of this mechanism, it may also support better overall glycemic control in people with Type 2 Diabetes, although its primary development focus has been weight management.

In clinical research, cagrilintide has often been studied in combination with other metabolic drugs, such as Semaglutide. This combination approach targets multiple appetite and metabolic pathways simultaneously, leading to greater reductions in body weight than either agent alone in early trials.

Common side effects are generally related to the gastrointestinal system and may include nausea, vomiting, or reduced appetite, especially during initial use. These effects are typically dose-dependent and may decrease over time.

In summary, cagrilintide is a promising anti-obesity peptide that works by mimicking amylin to reduce hunger, slow digestion, and improve post-meal glucose control, making it a valuable candidate in modern metabolic therapy research.

How Effective Is Cagrilintide For Weight Loss?

Cagrilintide is an experimental long-acting amylin analogue that has shown meaningful weight-loss effects in clinical research, both as a standalone therapy and especially in combination treatments. Its effectiveness comes from its ability to mimic the natural hormone amylin, which helps regulate appetite, gastric emptying, and satiety signaling in the brain.

As a monotherapy, cagrilintide produces moderate but clinically significant weight loss. In phase 2 and early phase 3 studies, weekly injections led to roughly 10–12% average body weight reduction over about 26–68 weeks, depending on dose and study design. This level of effect is considered strong for a single-mechanism drug targeting the amylin pathway, and it is generally associated with reduced food intake and improved fullness after meals.

However, its most impressive results appear when it is combined with GLP-1–based therapies such as Semaglutide. In combination (often called “CagriSema”), weight loss increases substantially, with clinical trials reporting average reductions of around 20% or more of initial body weight over longer treatment periods. Some studies show even higher results in fully adherent participants, with a significant proportion of patients achieving ≥20–25% weight loss.

Overall, cagrilintide alone is effective but modest compared to newer multi-target therapies, while its combination with GLP-1 drugs places it among the most powerful weight-loss pharmacological approaches currently in development. It is still investigational, meaning long-term safety, durability, and real-world outcomes are not yet fully established, but early data suggest strong potential for obesity treatment.

What Is The Mechanism Of Action Of Cagrilintide?

Cagrilintide is a long-acting synthetic analogue of the natural pancreatic hormone amylin, and its mechanism of action is centered on mimicking and enhancing amylin’s physiological roles in appetite and glucose regulation. It is primarily being developed for the treatment of obesity and metabolic disorders, including Type 2 Diabetes.

The main mechanism of cagrilintide involves binding to amylin receptors in the brain, particularly in regions of the hypothalamus and brainstem that regulate hunger and satiety. Activation of these receptors sends signals that increase feelings of fullness and reduce hunger, leading to decreased caloric intake. This central appetite-suppressing effect is one of the key drivers of its weight-loss potential.

In addition to its central nervous system effects, cagrilintide also slows gastric emptying. By delaying the movement of food from the stomach into the small intestine, it prolongs the sensation of fullness after meals and helps prevent rapid spikes in postprandial blood glucose levels. This contributes to better glycemic stability and improved metabolic control.

Cagrilintide also influences nutrient intake indirectly by reducing meal size and food-seeking behavior. Unlike some other weight-loss agents, it does not primarily act by increasing energy expenditure, but rather by lowering energy intake through appetite regulation and satiety enhancement.

In clinical research, cagrilintide has been studied alone and in combination with GLP-1 receptor agonists such as Semaglutide. These combination therapies target multiple hormonal pathways involved in appetite and metabolism, producing additive or even synergistic effects on weight reduction.

Overall, the mechanism of cagrilintide is best described as a centrally acting amylin receptor agonist that reduces hunger, enhances satiety, and slows gastric emptying, leading to decreased food intake and improved metabolic regulation.